Bura Sindhupakorn1, Darawan Jomkoh1, Theeranit Namkuntee1. 1. Orthopedic Department, School of Medicine, Suranaree Medical Institute, Suranaree University of Technology, 111 University Ave, Muang District, Nakhon Ratchasima Province, 30000, Thailand.
Abstract
BACKGROUND: Corticosteroid and Ketorolac tromethamine is a pain reducing. OBJECTIVE: The primary objective was pain intensity scores (VAS) in 10, 30, 60 min, 2, 6 h, 1, and 7 days. METHOD: 120 patients were randomized. The placebo group (normal saline) and experimental groups (ketorolac 30 mg, 60 mg, triamcinolone 10 mg, 20 mg, and 40 mg, respectively) were compared. RESULT: VAS at 60 min, 2, 6 h, 1 and 7 days was significantly different (P < 0.05). Ketorolac 30 mg, 60 mg, and triamcinolone 10 mg shown non inferiority to triamcinolone 40 mg. CONCLUSIONS: ketorolac was considered equal to triamcinolone.
BACKGROUND: Corticosteroid and Ketorolac tromethamine is a pain reducing. OBJECTIVE: The primary objective was pain intensity scores (VAS) in 10, 30, 60 min, 2, 6 h, 1, and 7 days. METHOD: 120 patients were randomized. The placebo group (normal saline) and experimental groups (ketorolac 30 mg, 60 mg, triamcinolone 10 mg, 20 mg, and 40 mg, respectively) were compared. RESULT: VAS at 60 min, 2, 6 h, 1 and 7 days was significantly different (P < 0.05). Ketorolac 30 mg, 60 mg, and triamcinolone 10 mg shown non inferiority to triamcinolone 40 mg. CONCLUSIONS: ketorolac was considered equal to triamcinolone.
Authors: Tero A H Järvinen; Teppo L N Järvinen; Minna Kääriäinen; Hannu Kalimo; Markku Järvinen Journal: Am J Sports Med Date: 2005-05 Impact factor: 6.202
Authors: Nynke Smidt; Willem J J Assendelft; Daniëlle A W M van der Windt; Elaine M Hay; Rachelle Buchbinder; Lex M Bouter Journal: Pain Date: 2002-03 Impact factor: 6.961